@curator

1 year ago

Article

Long-term outcomes following CAR T cell therapy: what we know so far - Nature Reviews Clinical Oncology

Rating: 0.0

Likes: 1

Library: 1

Long-term outcomes following CAR T cell therapy: what we know so far - Nature Reviews Clinical Oncology

Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now an established treatment for patients with relapsed and/or refractory B cell lymphomas, B cell acute lymphoblastic leukaemia and multiple myeloma. At the time of this writing, over a decade of follow-up data are available from the initial patients who received CD19-targeted CAR T cells for B cell malignancies.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Long-term outcomes following CAR T cell therapy: what we know so far - Nature Reviews Clinical Oncology

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Long-term outcomes following CAR T cell therapy: what we know so far - Nature Reviews Clinical Oncology

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress